Deyuan Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Deyuan Pan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- En-Min Li
Shantou University Medical College
1 shared publication - Li-Yan Xu
Shantou University Medical College
1 shared publication - Lin Long
Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, China
1 shared publication - Wanyi Liu
Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, China
1 shared publication - Xiaolu Tan
Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, China
1 shared publication - Xinglin He
Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, China
1 shared publication
Latest Publications
- Open Access
- 5 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (3) , 477
Friend or Foe: Regulation, Downstream Effectors of RRAD in Cancer
Ras-related associated with diabetes (RRAD), a member of the Ras-related GTPase superfamily, is primarily a cytosolic protein that actives in the plasma membrane. RRAD is highly expressed in type 2 diabetes patients and as a biomarker of congestive heart failure. Mounting evidence showed that RRAD is important for the progression and metastasis of tumor cells, which play opposite roles as an oncogene or tumor suppressor gene depending on cancer and cell type. These findings are of great significance, especially given that relevant molecular mechanisms are being discovered. Being regulated in various pathways, RRAD plays wide spectrum cellular activity including tumor cell division, motility, apoptosis, and energy metabolism by modulating tumor-related gene expression and interacting with multiple downstream effectors. Additionally, RRAD in senescence may contribute to its role in cancer. Despite the twofold characters of RRAD, targeted therapies are becoming a potential therapeutic strategy to combat cancers. This review will discuss the dual identity of RRAD in specific cancer type, provides an overview of the regulation and downstream effectors of RRAD to offer valuable insights for readers, explore the intracellular role of RRAD in cancer, and give a reference for future mechanistic studies.
- 5 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (3) , 477
Open AccessFriend or Foe: Regulation, Downstream Effectors of RRAD in Cancer
Ras-related associated with diabetes (RRAD), a member of the Ras-related GTPase superfamily, is primarily a cytosolic protein that actives in the plasma membrane. RRAD is highly expressed in type 2 diabetes patients and as a biomarker of congestive heart failure. Mounting evidence showed that RRAD is important for the progression and metastasis of tumor cells, which play opposite roles as an oncogene or tumor suppressor gene depending on cancer and cell type. These findings are of great significance, especially given that relevant molecular mechanisms are being discovered. Being regulated in various pathways, RRAD plays wide spectrum cellular activity including tumor cell division, motility, apoptosis, and energy metabolism by modulating tumor-related gene expression and interacting with multiple downstream effectors. Additionally, RRAD in senescence may contribute to its role in cancer. Despite the twofold characters of RRAD, targeted therapies are becoming a potential therapeutic strategy to combat cancers. This review will discuss the dual identity of RRAD in specific cancer type, provides an overview of the regulation and downstream effectors of RRAD to offer valuable insights for readers, explore the intracellular role of RRAD in cancer, and give a reference for future mechanistic studies.